The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

The table below is a review of notable updates that occurred in January 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

Tirzepatide and lifestyle modification generated 48,649 life-years gained per 100,000 eligible individuals, and semaglutide and lifestyle modification generated 35,634 life-years gained per ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

The cost of Ozempic can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Ozempic. Ozempic belongs to a ...